SCHEMBL20258285

SCHEMBL20258285

CC(C)(C)OC(=O)N1C[C@H](N(OCc2ccccc2)C(=O)Cl)CC[C@]1(C(=O)O)N1C(=O)C2CCCCC2C1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
KMT2A Q03164 4/20 0.33
L3MBTL1 Q9Y468 3/20 0.33
MEN1 O00255 2/20 0.33
ALDH1A1 P00352 1/20 0.33
PDE4B Q07343 2/20 0.33
PDE4A P27815 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
STS P08842 1/20 0.33
TACR1 P25103 2/20 0.32
HSD11B1 P28845 1/20 0.32
USP30 Q70CQ3 1/20 0.32
KLK7 P49862 1/20 0.32
FKBP1A P62942 1/20 0.32
HTR2C P28335 1/20 0.31
SLC6A4 P31645 1/20 0.31
PRMT5 O14744 1/20 0.31
PARP1 P09874 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17956498 1.00 JAK2 (0.36) JAK2JAK1KMT2AL3MBTL1MEN1
SCHEMBL20258281 0.93 JAK2 (0.36) JAK2JAK1KMT2AL3MBTL1MEN1
SCHEMBL19409528 0.93 JAK2 (0.36) JAK2JAK1KMT2AL3MBTL1MEN1
SCHEMBL20258273 0.91 JAK2 (0.33) JAK2JAK1KMT2AL3MBTL1MEN1
SCHEMBL17956500 0.91 JAK2 (0.33) JAK2JAK1KMT2AL3MBTL1MEN1
SCHEMBL17956383 0.89 JAK2 (0.38) JAK2JAK1KMT2AL3MBTL1MEN1
SCHEMBL17956410 0.89 JAK2 (0.35) JAK2JAK1KMT2AL3MBTL1MEN1
SCHEMBL17956509 0.89 JAK2 (0.35) JAK2JAK1KMT2AL3MBTL1MEN1
SCHEMBL17956458 0.89 JAK2 (0.37) JAK2JAK1KMT2AL3MBTL1MEN1
SCHEMBL20258294 0.84 JAK2 (0.33) JAK2JAK1KMT2AL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000491-B2 Process for producing diazabicyclooctane derivative and intermediate thereof MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000491-B2 Process for producing diazabicyclooctane derivative and intermediate thereof CLCN2, ODC1, KCNN4 JAK2 1743/4885JAK1 3157/4885KMT2A 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.